Aeterna Zentaris (AEZS) | Stock Overview & Key Data
Aeterna Zentaris Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $9.32 on May 13, 2024
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Jun 30, 2024
Annual Income Flow
2023
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Aeterna Zentaris
AEZS
|
N/A | N/A | N/A | N/A | N/A | N/A | 1,281.48% | 677.08% | 1,186.21% | 856.41% | 856.41% | 856.41% |
|
Vertex
VRTX
|
109.45B Large-cap | 1.69% | 3.09% | -3.36% | -1.15% | -0.37% | -2.31% | 27.89% | 136.85% | 413.01% | 888.51% | 1,245.83% |
|
Regeneron
REGN
|
80.98B Large-cap | 0.60% | -11.93% | -18.75% | -18.29% | -20.78% | 15.66% | -21.83% | 13.80% | 72.82% | 1,033.17% | 4,804.97% |
|
Alnylam
ALNY
|
41.87B Large-cap | -1.49% | 0.29% | -9.76% | -26.49% | -28.08% | -8.16% | 40.32% | 59.90% | 405.36% | 3,032.34% | 1,907.45% |
|
Royalty Pharma plc
RPRX
|
29.43B Large-cap | -1.08% | 2.69% | 17.72% | 40.85% | 39.66% | 57.49% | 72.01% | 24.65% | 11.98% | 11.98% | 11.98% |
|
Insmed
INSM
|
31.05B Large-cap | 3.49% | -10.70% | -32.60% | -50.51% | -44.98% | -0.89% | 389.25% | 236.25% | 934.36% | 717.46% | 614.23% |
Ownership & Short Interest
Calculate Your Aeterna Zentaris Investment Returns
Long-Term Investment Performance Analysis
Aeterna Zentaris stock price in Aug 2018 was $0.39, A $1,000.00 lump sum investment in Aeterna Zentaris made 6 years ago would be worth approximately $9,564.10 today, representing a exceptional return of 856.41%. This translates to an annualized return (CAGR) of 39.16%.
6 Years 10 Months Investment Scenario (Aug 2018 - Jun 2025)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is AEZS's 52-week high and low?
- In the last 52 weeks, Aeterna Zentaris reached a high of $9.32 (on May 15, 2024) and a low of $0.15 (on N/A).
- What is the market cap and P/E ratio for AEZS?
- Curious about Aeterna Zentaris's size and valuation? Its market capitalization stands at N/A. When it comes to valuation, the P/E ratio (trailing twelve months) is -1.95, and the forward P/E (looking ahead) is -1.70.
- Does AEZS pay dividends? If so, what's the yield?
- As for dividends, Aeterna Zentaris isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Aeterna Zentaris's main competitors or similar companies to consider before investing?
When looking at Aeterna Zentaris, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX109.45B Healthcare Biotechnology -2.31% 27.89% Regeneron
REGN80.98B Healthcare Biotechnology 15.66% -21.83% Alnylam
ALNY41.87B Healthcare Biotechnology -8.16% 40.32% Royalty Pharma plc
RPRX29.43B Healthcare Biotechnology 57.49% 72.01% Insmed
INSM31.05B Healthcare Biotechnology -0.89% 389.25% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Aeterna Zentaris Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Aeterna Zentaris's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -81.71%, the Debt to Equity ratio from the most recent quarter is 1.80, and its Gross Profit Margin stands at 35.04%.
- What is the recent revenue and earnings growth for AEZS?
- Looking at Aeterna Zentaris's growth, its revenue over the trailing twelve months (TTM) was $2M. Compared to the same quarter last year (YoY), quarterly revenue grew by -99.80%, and quarterly earnings saw a YoY growth of 129.94%.
- How much of AEZS stock is held by insiders and institutions?
- Wondering who owns Aeterna Zentaris stock? Company insiders (like executives and directors) hold about 1.32% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 5.21%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.